行业周报：供需双改善，国内临床CRO行业进入发展新阶段-20260201

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The Chinese clinical CRO industry is entering a new phase of "recovery and stable growth," with continuous improvement in supply-demand structure [4][14] - The Chinese innovative drug industry has transitioned from an "offshore outsourcing service model" to a "global contributor of innovative assets" over the past decade [4] - The clinical CRO market is expected to achieve a CAGR of over 12% from 2025 to 2028, with the market size projected to exceed 75 billion RMB by 2028 [4][14] - The number of clinical trials in both China and the US is increasing, while the domestic CRO market is experiencing a gradual clearing of excess capacity, leading to a higher concentration of market share among leading companies [4][17] Summary by Sections 1. Clinical CRO Market Recovery and Stable Growth - The clinical CRO market in China is expected to enter a new phase of recovery and stable growth, with a projected CAGR of over 12% from 2025 to 2028 [4][14] - The average number of clinical trial projects per CRO in China has increased by 20.6% year-on-year, reaching 42.9 projects, narrowing the gap with the US [17][22] - The demand side shows a simultaneous increase in the number of clinical trials in both China and the US, while the supply side continues to clear excess capacity [17] 2. License-out and M&A as New Financing Norms - In the context of a slowing IPO rhythm, license-out and M&A have become the core channels for financing in the Chinese biotech sector [5][21] - The number of licensing transactions for innovative drug assets in China has significantly increased, with total transactions reaching 178 [21][23] 3. Tigermed's Development and Order Growth - Tigermed, as a leading clinical CRO in China, has seen a compound annual growth rate of new orders at 14.8%, surpassing the overall market growth rate [6][25] - The average price of domestic clinical trials is stabilizing after fluctuations in 2022-2023, providing strong support for order quality and profitability recovery [6][25] - Tigermed's acquisition of Micron enhances its capabilities in medical imaging and expands its influence in the Asia-Pacific region [30] 4. Market Performance Overview - In January's fourth week, the pharmaceutical and biological sector fell by 3.31%, underperforming the CSI 300 index by 3.39 percentage points [33][36] - The blood products sector experienced the smallest decline, while the offline pharmacy sector saw the largest drop [38][40]